 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456789» |
- | Trial completion date, Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 20, 2019
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020
- | pretomanid (PA-824) / Global Alliance for TB Drug Development, Lamprene (clofazimine) / Novartis, Sirturo (bedaquiline) / J&J, Pharmstandard
New P2/3 trial, HEOR: PRACTECAL-PRO: Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial (clinicaltrials.gov) - May 7, 2019
P2/3, N=54, Not yet recruiting, Sponsor: Medecins Sans Frontieres, Netherlands
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial primary completion date: Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) (clinicaltrials.gov) - Apr 23, 2019
P3, N=180, Recruiting, Sponsor: Global Alliance for TB Drug Development
Trial completion date: Sep 2019 --> Sep 2020 | Trial primary completion date: Jun 2019 --> Sep 2020 Trial primary completion date: Apr 2021 --> Dec 2020
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function (clinicaltrials.gov) - Apr 1, 2019
P1, N=48, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment change: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Mar 26, 2019
P3, N=284, Completed, Sponsor: Global Alliance for TB Drug Development
Trial primary completion date: Apr 2021 --> Dec 2020 N=1500 --> 284
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial primary completion date: Pretomanid in Adults With Hepatic Impairment (clinicaltrials.gov) - Mar 1, 2019
P1, N=36, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=1500 --> 284 Trial primary completion date: Mar 2019 --> Jun 2019
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Phase classification: Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients (clinicaltrials.gov) - Feb 6, 2019
P2/3, N=450, Recruiting, Sponsor: Global Alliance for TB Drug Development
Trial primary completion date: Mar 2019 --> Jun 2019 Phase classification: P2 --> P2/3
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial primary completion date: Nix-TB: A Phase 3 Study Assessing Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Dec 24, 2018
P3, N=109, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Phase classification: P2 --> P2/3 Trial primary completion date: Oct 2018 --> Feb 2019
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial completion date, Trial primary completion date: Assessing PA-824 for Tuberculosis (the APT Trial) (clinicaltrials.gov) - Nov 9, 2018
P2, N=183, Recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Oct 2018 --> Feb 2019 Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2019 --> Sep 2020
- |||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open, Trial primary completion date: Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients (clinicaltrials.gov) - Aug 8, 2018
P2, N=450, Recruiting, Sponsor: Global Alliance for TB Drug Development
Trial completion date: Sep 2019 --> Sep 2021 | Trial primary completion date: Sep 2019 --> Sep 2020 Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2021 --> Mar 2020
- ||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial completion: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Jul 18, 2018
P3, N=1500, Completed, Sponsor: Global Alliance for TB Drug Development
Not yet recruiting --> Recruiting | Trial primary completion date: Aug 2021 --> Mar 2020 Active, not recruiting --> Completed
- | Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 2, 2018
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Mar 2018 --> Jun 2019
- |||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open: Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) (clinicaltrials.gov) - Jan 25, 2018
P3, N=180, Recruiting, Sponsor: Global Alliance for TB Drug Development
Trial primary completion date: Mar 2018 --> Jun 2019 Not yet recruiting --> Recruiting
- ||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: Nix-TB: A Phase 3 Study Assessing Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Jan 11, 2018
P3, N=200, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open, Trial initiation date, Trial primary completion date: Pretomanid in Adults With Hepatic Impairment (clinicaltrials.gov) - Jan 2, 2018
P1, N=36, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Suspended --> Recruiting | Initiation date: Sep 2015 --> Dec 2017 | Trial primary completion date: Oct 2016 --> Mar 2019
- ||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
New P2 trial: Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients (clinicaltrials.gov) - Nov 9, 2017
P2, N=450, Not yet recruiting, Sponsor: Global Alliance for TB Drug Development
- | Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Oct 7, 2017
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Suspended --> Recruiting | Initiation date: Sep 2015 --> Dec 2017 | Trial primary completion date: Oct 2016 --> Mar 2019 Trial primary completion date: Jun 2019 --> Mar 2018
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open, Trial primary completion date: Assessing PA-824 for Tuberculosis (the APT Trial) (clinicaltrials.gov) - Aug 28, 2017
P2, N=183, Recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Jun 2019 --> Mar 2018 Suspended --> Recruiting | Trial primary completion date: Feb 2018 --> Sep 2019
- |||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial primary completion date: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Aug 22, 2017
P3, N=1500, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Suspended --> Recruiting | Trial primary completion date: Feb 2018 --> Sep 2019 Trial primary completion date: Jun 2017 --> Jan 2018
- pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: CL-004: A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects. (clinicaltrials.gov) - Jun 27, 2017
P1, N=6, Completed, Sponsor: Global Alliance for TB Drug Development
- | Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Apr 7, 2017
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2017 --> Jan 2018 Trial primary completion date: Jun 2018 --> Jun 2019
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
New P3 trial: Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) (clinicaltrials.gov) - Mar 22, 2017
P3, N=180, Not yet recruiting, Sponsor: Global Alliance for TB Drug Development
- |||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard
Enrollment open, Trial initiation date, Trial primary completion date: TB-PRACTECAL: Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (clinicaltrials.gov) - Jan 18, 2017
P2/3, N=630, Recruiting, Sponsor: Medecins Sans Frontieres, Netherlands
Trial primary completion date: Jun 2018 --> Jun 2019 Not yet recruiting --> Recruiting | Initiation date: Feb 2016 --> Jan 2017 | Trial primary completion date: Jun 2019 --> Jun 2020
- ||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Dec 21, 2016
P3, N=1500, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Not yet recruiting --> Recruiting | Initiation date: Feb 2016 --> Jan 2017 | Trial primary completion date: Jun 2019 --> Jun 2020 Suspended --> Active, not recruiting
- Enrollment change: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Feb 29, 2016
P4, N=1786, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Suspended --> Active, not recruiting N=1300 --> 1786
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial suspension: Assessing PA-824 for Tuberculosis (the APT Trial) (clinicaltrials.gov) - Feb 2, 2016
P2, N=183, Suspended, Sponsor: Johns Hopkins University
N=1300 --> 1786 Recruiting --> Suspended
- ||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (clinicaltrials.gov) - Dec 17, 2015
P2, N=240, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Recruiting --> Suspended Recruiting --> Active, not recruiting
- || pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial suspension: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Nov 3, 2015
P3, N=1500, Suspended, Sponsor: Global Alliance for TB Drug Development
Recruiting --> Active, not recruiting Recruiting --> Suspended
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development, Sirturo (bedaquiline) / J&J, Pharmstandard
New P2/3 trial: TB-PRACTECAL: Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) (clinicaltrials.gov) - Oct 28, 2015
P2/3, N=630, Not yet recruiting, Sponsor: Medecins Sans Frontieres
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial suspension: Pretomanid in Adults With Hepatic Impairment (clinicaltrials.gov) - Oct 22, 2015
P1, N=36, Suspended, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Suspended Recruiting --> Suspended
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open: Pretomanid in Adults With Hepatic Impairment (clinicaltrials.gov) - Oct 5, 2015
P1, N=36, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Suspended Not yet recruiting --> Recruiting
- |||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open: Assessing PA-824 for Tuberculosis (the APT Trial) (clinicaltrials.gov) - Jul 2, 2015
P2, N=183, Recruiting, Sponsor: Johns Hopkins University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Apr 28, 2015
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: May 2016 --> Jun 2018
- pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: Pretomanid in Adults With Hepatic Impairment (clinicaltrials.gov) - Apr 21, 2015
P1, N=36, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open: Nix-TB: A Phase 3 Study Assessing Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Mar 26, 2015
P3, N=200, Recruiting, Sponsor: Global Alliance for TB Drug Development
Trial primary completion date: May 2016 --> Jun 2018 Not yet recruiting --> Recruiting
- |||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Feb 20, 2015
P3, N=1500, Recruiting, Sponsor: Global Alliance for TB Drug Development
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
New P3 trial: STAND: Shortening Treatment by Advancing Novel Drugs (clinicaltrials.gov) - Jan 22, 2015
P3, N=1500, Not yet recruiting, Sponsor: Global Alliance for TB Drug Development
- |||| pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment open: A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (clinicaltrials.gov) - Jan 7, 2015
P2, N=240, Recruiting, Sponsor: Global Alliance for TB Drug Development
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
New P3 trial: Nix-TB: A Phase 3 Study Assessing Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis (clinicaltrials.gov) - Jan 7, 2015
P3, N=200, Not yet recruiting, Sponsor: Global Alliance for TB Drug Development
- ||||| pretomanid (PA-824) / Global Alliance for TB Drug Development
New P2 trial: Assessing PA-824 for Tuberculosis (the APT Trial) (clinicaltrials.gov) - Oct 10, 2014
P2, N=183, Not yet recruiting, Sponsor: Johns Hopkins University
- | pretomanid (PA-824) / Global Alliance for TB Drug Development
New P2 trial: A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. (clinicaltrials.gov) - Jul 18, 2014
P2, N=240, Not yet recruiting, Sponsor: Global Alliance for TB Drug Development
- Trial primary completion date: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - May 5, 2014
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Trial primary completion date: May 2014 --> May 2016
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial completion: Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin (clinicaltrials.gov) - Sep 29, 2013
P1, N=52, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: May 2014 --> May 2016 Recruiting --> Completed
- pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009) (clinicaltrials.gov) - Apr 10, 2013
P1, N=32, Completed, Sponsor: Global Alliance for TB Drug Development
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) (clinicaltrials.gov) - Apr 10, 2013
P2, N=105, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Recruiting --> Completed Recruiting --> Active, not recruiting
- pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: CL-003: Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (clinicaltrials.gov) - Apr 9, 2013
P1, N=16, Completed, Sponsor: Global Alliance for TB Drug Development
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Enrollment closed: Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002) (clinicaltrials.gov) - Mar 11, 2013
P2, N=230, Active, not recruiting, Sponsor: Global Alliance for TB Drug Development
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- pretomanid (PA-824) / Global Alliance for TB Drug Development
Trial completion: Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers (clinicaltrials.gov) - Feb 13, 2013
P1, N=74, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Completed
- Enrollment change: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy (clinicaltrials.gov) - Feb 11, 2013
P4, N=1300, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed N=800 --> 1300
- pretomanid (PA-824) / Global Alliance for TB Drug Development
New P1 trial: Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam (clinicaltrials.gov) - Jan 13, 2013
P1, N=14, Completed, Sponsor: Global Alliance for TB Drug Development